Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
!!Search content at Mayo Clinic
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Myc matters in HIV-associated lymphoma
Thomas E. Witzig
Hematology
Research output
:
Contribution to journal
›
Review article
›
peer-review
1
!!Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Myc matters in HIV-associated lymphoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
HIV-associated Lymphoma
100%
R-EPOCH
100%
Histone Deacetylase Inhibitor (HDACi)
75%
Vorinostat
50%
Preclinical Data
25%
Tumor
25%
Overall Survival
25%
Event-free Survival
25%
Doxorubicin
25%
Survival Rate
25%
Phase II Trial
25%
Epstein-Barr Virus
25%
Diffuse Large B-cell Lymphoma (DLBCL)
25%
Cyclophosphamide
25%
Rituximab
25%
HIV Infection
25%
HIV-associated
25%
Randomized Phase II Trial
25%
Complete Remission
25%
Prednisone
25%
Etoposide
25%
Patients with HIV
25%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Histone Deacetylase Inhibitor
75%
Vorinostat
50%
Overall Survival
25%
Event Free Survival
25%
Doxorubicin
25%
Survival Rate
25%
Epstein Barr Virus
25%
Diffuse Large B-Cell Lymphoma
25%
Cyclophosphamide
25%
Spontaneous Remission
25%
Rituximab
25%
Etoposide
25%
Spine
25%
Prednisone
25%
Human Immunodeficiency Virus Infection
25%
Vincristine
25%
Tumor
25%
Oral
25%